- Home
- PCYO vs RLMD Comparison
PCYO vs RLMD Comparison
Compare PCYO & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PCYO | RLMD |
|---|---|---|
| Founded | 1976 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 267.7M | 307.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PCYO | RLMD |
|---|---|---|
| Price | $11.86 | $4.32 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 47.9K | ★ 1.1M |
| Earning Date | 01-07-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.50 | N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $26,087,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.11 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.65 | $0.24 |
| 52 Week High | $14.09 | $5.12 |
Technical Indicators
Market Signals| Indicator | PCYO | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 61.92 | 61.38 |
| Support Level | $11.61 | $3.95 |
| Resistance Level | $12.12 | $4.72 |
| Average True Range (ATR) | 0.34 | 0.46 |
| MACD | 0.05 | -0.07 |
| Stochastic Oscillator | 74.68 | 62.79 |
Price Performance
Historical ComparisonAbout PCYO Pure Cycle Corporation
Pure Cycle Corp is a diversified land and water resource development company. The company designs, constructs, manages, operates, and maintains water and wastewater systems. The firm operates in two business segments namely Water and wastewater resource development and Land development. It generates maximum revenue from the Land development segment. The land resource development segment includes all the activities necessary to develop and sell finished lots.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.